INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 15 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,195,058 | -24.3% | 7,295,000 | -38.3% | 0.10% | -16.8% |
| Q2 2023 | $9,508,858 | +30.4% | 11,824,000 | +34.1% | 0.12% | +54.3% |
| Q1 2023 | $7,289,292 | +15.7% | 8,816,000 | +5.0% | 0.08% | +22.7% |
| Q4 2022 | $6,300,448 | +40.5% | 8,395,000 | +41.4% | 0.07% | +34.7% |
| Q3 2022 | $4,484,000 | – | 5,937,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $34,742,000 | 1.33% |
| PenderFund Capital Management Ltd. | 5,000,000 | $3,839,000 | 0.98% |
| Context Capital Management, LLC | 7,485,000 | $4,494,000 | 0.62% |
| Opti Capital Management, LP | 7,000,000 | $4,250,000 | 0.47% |
| Soros Fund Management | 32,298,000 | $19,611,000 | 0.37% |
| Shaolin Capital Management LLC | 7,000,000 | $4,175,000 | 0.29% |
| Weiss Asset Management LP | 3,500,000 | $2,084,000 | 0.09% |
| CSS LLC/IL | 2,825,000 | $1,681,000 | 0.06% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $137,000 | 0.02% |
| LAZARD ASSET MANAGEMENT LLC | 25,000,000 | $15,009,000 | 0.02% |